{"entity":{"id":"nct03937154","kind":"trial","name":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer","aka":[],"tldr":"A phase 3 trial of Romiplostim in non-small-cell lung cancer, run by Amgen, active and no longer recruiting.","summary":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer is a phase 3 interventional study registered as NCT03937154 by Amgen, with 145 participants enrolled, started 2020-02-26 and due to reach its primary completion in 2026-03-10. Interventions recorded: Romiplostim and Placebo.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03937154","url":"https://clinicaltrials.gov/study/NCT03937154"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["romiplostim"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03937154","phase":"3","setting":"PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer","sponsor":"Amgen","enrolled":145,"outcomes":[]},"route":"/trials/nct03937154/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"romiplostim","kind":"drug","name":"Romiplostim","route":"/drugs/romiplostim/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}